Direkt zum Inhalt
Merck

Design, synthesis and in vitro anticancer evaluation of a stearic acid-based ester conjugate.

Anticancer research (2013-06-12)
Azmat Ali Khan, Amer M Alanazi, Mumtaz Jabeen, Arun Chauhan, Ali Sabir Abdelhameed
ZUSAMMENFASSUNG

Chemical synthesis and characterization of a lipophilic ester conjugate, propofol stearate and evaluation of its anticancer efficacy on human breast cancer cell lines MDA-MB-361, MCF-7 and MDA-MB-231. The chemical structure of the synthesized conjugate was characterized by spectroscopic studies. Its anticancer potential was evaluated on the basis of growth inhibition, cancer cell adhesion and migration and apoptosis induction. Propofol stearate exhibited significant (p<0.05) growth inhibition of breast cancer cells in a concentration-dependent manner. MDA-MB-231 cells showed highest susceptibility towards the inhibitory effect of the conjugate. Moreover, treatment of MDA-MB-231 cancer cells with 25 μM propofol stearate potentially suppressed their adhesion (~34%) and migration (~41%), and induced apoptosis (~25%). Exogenously-applied stearic acid as an ester derivative, inhibits the growth of human breast cancer cells and shows a beneficial role in the treatment of breast cancer, in vitro.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Stearinsäure, Grade I, ≥98.5% (capillary GC)
Sigma-Aldrich
Stearinsäure, reagent grade, 95%
Sigma-Aldrich
Stearinsäure, ≥95%, FCC, FG
Supelco
Stearinsäure, analytical standard
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Supelco
Stearinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Stearinsäure, European Pharmacopoeia (EP) Reference Standard
Propofol, European Pharmacopoeia (EP) Reference Standard
Supelco
Stearinsäure, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Propofol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard